Clinical Trial Update: Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial exploring Garsorasib followed by Ivonescimab plus chemotherapy in resectable stage IIA-IIIB KRAS G12C-mutant non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Garsorasib
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Lung Cancer (NSCLC), KRAS G12C Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING